# Daclatasvir

## Daklinza 60mg

##### 臨採

| TAH Drug Code      | [ODAK](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ODAK)                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Chronic hepatitis C: Treatment of chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection in combination with sofosbuvir, with or without ribavirin                                                                                                                                                                                                                                                                           |
| Dosing             | Not indicated as monotherapy. The American Association for the Study of Liver Diseases/Infectious Diseases Society of America guidelines for testing, managing, and treating hepatitis C no longer include daclatasvir as a component of recommended treatment regimens for hepatitis C virus infection (AASLD/IDSA 2020). (仿單) 60 mg orally once daily with or without food in combination with other agents for chronic hepatitis C. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                            |
| Contraindications  | Concurrent use of strong CYP3A inducers (eg, carbamazepine, phenytoin, rifampin, St John's wort). When used in combination with other agents (eg, ribavirin), the contraindications to those agents also apply (refer to respective labeling information).                                                                                                                                                                               |
| Adverse Effects    | >10%: Central nervous system: Fatigue (14% to 15%), headache (12% to 14%) Gastrointestinal: Nausea (8% to 15%) Hematologic & Oncologic: Anemia (20%) 1~10% Central nervous system: Drowsiness (5%), insomnia (3%) Dermatologic: Skin rash (8%) Gastrointestinal: Diarrhea (3% to 5%), increased serum lipase (>3x ULN, transient)                                                                                                        |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                   |
| Lactation          | No (Limited) Human Data – Potential Toxicity(Mother)                                                                                                                                                                                                                                                                                                                                                                                     |
| More Info          | [UpToDate](https://www.uptodate.com/contents/daclatasvir-international-drug-information-concise)                                                                                                                                                                                                                                                                                                                                         |

